Knight Therapeutics Inc.

GUD.TOTSXHealthcare● Active

$9.11

+$0.50(+5.81%)

Market Cap$893096117

P/E Ratio—

52W High$9.15

52W Low$5.66

Avg Volume87K

Open$8.50

Beta0.07

Net Income Financials Revenue

Knight Therapeutics Inc. (GUD.TO) Net Income & Profit History

Annual & trailing net income, net margin, YoY change, and peer profitability context.

GUD.TO · net income · updated Jun 8, 2026

Core profitability metrics

GUD.TO · net income · margin · TTM · CAGR

Net income was −$5.4M for FY2025 (fiscal year ending 2025-12-31), down 224.1% year-over-year. Net profit margin was -1.2%. Based on available data, Knight Therapeutics Inc. has been profitable since at least 2014.

FY2025 Net Income−$5.4M▼ -224.1% YoY

Trailing 12M (TTM)$5.6Mtrailing 4 quarters sum

Net Profit Margin-1.2%−$5.4M ÷ $450.1M

YoY Change-224.1%—

5-Year CAGRN/AN/A — contains loss years

FormulaNet Margin = Net Income ÷ Revenue × 100TTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /income-statement · US GAAP · USDUpdated: Jun 8, 2026

Annual net income history

Net Income (bars) · Net Profit Margin % (line)

Net IncomeNet LossNet Margin %★ First Profit: 2014

▸ FMP /income-statement · Annual · GUD.TO net income history · GUD.TO profit margin

Annual net income data

GUD.TO · net income history · annual / quarterly

Fiscal YearNet IncomeYoY ChangeNet MarginRevenue

FY2025Loss−$5.4M▼ 224.1%-1.2%$450.1M

FY2024$4.3M▲ +125.7%1.2%$371.3M

FY2023Loss−$16.8M▲ +43.7%-5.1%$328.2M

FY2022Loss−$29.9M▼ 290.7%-10.2%$293.6M

FY2021$15.7M▼ 50.6%6.4%$243.5M

Net income vs peers (Healthcare)

GUD.TO vs peers · net income

#CompanyNet IncomeYoYNet MarginRelative

Knight Therapeutics Inc.YOU

GUD.TO

−$5.4M-224.1%-1.2%

Loss

Eli Lilly and Company

LLY

$20.64B+94.9%31.7%

77%

UnitedHealth Group Incorporated

Healthcare · Sorted by Net Income · FMP /income-statementFull Net Income Rankings →

About Net Income & Methodology

Knight Therapeutics Inc. (GUD.TO) reported net income of −$5.4M for FY2025 (fiscal year ending 2025-12-31), down 224.1% year-over-year. The net profit margin was -1.2% — meaning the company kept $-0.01 of every dollar of revenue as profit.

Based on available data, Knight Therapeutics Inc. has been profitable since at least 2014. Net income reached a peak of $125.9M in FY2014. Data available for 12 fiscal years.

Knight Therapeutics Inc.'s net profit margin was -1.2% for FY2025, based on the latest annual results.

Investors sometimes search for "Knight Therapeutics Inc. net worth" — the company's market capitalization is a separate figure from GUD.TO net income. Data sourced from FMP /income-statement · US GAAP · USD.

Figures tie to SEC 10-K/10-Q and FMP /income-statement where noted.

Revenue Financial statements Earnings Forecast Price history Market cap Free cash flow

Frequently asked questions

GUD.TO net income · 5 questions

Knight Therapeutics Inc. is not currently profitable on an annual basis. The company reported a net loss of $5.4M for FY2025.

is GUD.TO profitabledoes GUD.TO make a profitGUD.TO profitabilityGUD.TO profitable company

▸ Source: FMP /income-statement · GAAP · Knight Therapeutics Inc. · Knight Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026